Results 51 to 60 of about 11,226 (207)

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta‐Analysis of the European Myeloma Network (EMN)

American Journal of Hematology, EarlyView.
Our meta‐analysis showed significant improvement of PFS with lenalidomide, proteasome inhibitors, and CD38‐based therapies. A significant OS benefit was noted only with lenalidomide in transplant‐eligible (TE) patients, while CD38‐directed therapy showed a trend toward improved OS.
Heinz Ludwig, Evangelos Terpos, Francesca Gay, Niels W. C. J. van de Donk, Sarah Bernhard, Monika Engelhardt, Gordon Cook, Fredrik Schjesvold, Hermann Einsele, Graham Jackson, Charlotte Pawlyn, María‐Victoria Mateos, Sonja Zweegman, Martin Schreder, Meral Beksaç, Christoph Driessen, Enrique M. Ocio, Rakesh Popat, Leo Rasche, Cyrille Touzeau, Pellegrino Musto, Annemiek Broijl, Meletios Dimopoulos, Roman Hajek, Mario Boccadoro, Pieter Sonneveld   +25 more
wiley   +1 more source

Affinity Peptides With pH Sensitivity for the Enrichment of CD38+ Cells

Biotechnology and Bioengineering, EarlyView.
ABSTRACT The selective enrichment of cell populations based on surface markers is critical for the advancement of gene and cell therapies. Current antibody‐based cell isolation methods, such as fluorescence‐ and magnetic‐activated cell sorting (FACS and MACS), offer high specificity but are limited by scalability, cost, and potential adverse effects on
Gabrielle Rusch, Mickael Meyer, I. Mohamed Irfan, Carson Huber, Joseph Burclaff, Scott T. Magness, Stefano Menegatti, Michael Daniele   +7 more
wiley   +1 more source

Bioinorganic Site‐Specific Conjugation of Multi‐Arm Linkers to Create Pharmaceuticals With Targeting and Effector Functions

Journal of the Chinese Chemical Society, EarlyView.
This Account showcases a modular, multi‐arm linker platform that decouples payload loading from antibody conjugation. By leveraging a computationally designed ACPGHA zinc‐binding motif, we demonstrate the construction of homogeneous antibody‐drug conjugates and theranostic antibody‐radionuclide conjugates with high payload loading. The multi‐arm linker
Cédric Grauffel, Tse Wen Chang, Carmay Lim   +2 more
wiley   +1 more source

Daratumumab for Immunoglobulin Light Chain Amyloidosis

, 2021
Immunoglobulin light chain (AL) amyloidosis is characterized by small, indolent plasma cell clones that uniformly demonstrate high expression of CD38 surface molecule and produce toxic, free light chains.
Theodorakakou, Foteini, Dimopoulos, Meletios A., Kastritis, Efstathios   +2 more
core  

Daratumumab for the treatment of multiple myeloma

, 2017
International audienceProteasome inhibitors and immunomodulatory drugs have contributed to the dramatic improvement in survival for patients with myeloma over the past decades.
Touzeau, Cyrille, Cyrille Touzeau, Moreau, Philippe, Philippe Moreau   +3 more
core   +2 more sources

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

Journal of Hematology & Oncology, 2016
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including ...
Larysa Sanchez, Yucai Wang, David S. Siegel, Michael L. Wang   +3 more
doaj   +1 more source

A Refractory Leg Skin Ulcer Associated With Multiple Myeloma Successfully Treated With Plasma Exchange, Lenalidomide, and Dexamethasone

JEADV Clinical Practice, EarlyView.
ABSTRACT Multiple myeloma (MM) is a malignant plasma cell disorder that primarily presents with CRAB symptoms (calcium elevation, renal failure, anemia, and bone abnormalities). In rare cases, MM manifests with systemic complications like skin ulcers, which present management challenges. Here, we report a 78‐year‐old Japanese man with MM and refractory
Naoko Hattori, Yutaka Kuwatsuka, Tomoka Waseda, Daisuke Ehara, Koji Ando, Hiroyuki Murota   +5 more
wiley   +1 more source

Daratumumab: Therapeutic asset, biological trap!

, 2018
OBJECTIVES : Recently, daratumumab has been included in the therapeutic strategies for myeloma patients. This molecule is an antibody directed against CD38, strongly expressed on plasma cells. Nevertheless, as CD38 is also present on erythrocyte membrane,
Doyen, Chantal, Martin, Benoît, C. Debry, Thiry, Claire, C. Doyen, Deneys, Véronique, Frélik, Alex, B. Martin, V. Deneys, Debry, Cécile, C. Thiry, A. Frelik   +11 more
core   +1 more source

Case report: Daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of de novo donor-specific antibodies

Frontiers in Immunology, 2023
BackgroundLate or chronic active antibody-mediated rejection (AMR) associated with de novo donor-specific antibodies (dnDSA) after renal transplantation is a great clinical challenge because it is often resistant to conventional therapies.
Lan Zhu, Lan Zhu, Lan Zhu, Lan Zhu, Zhiliang Guo, Daqiang Zhao, Daqiang Zhao, Daqiang Zhao, Daqiang Zhao, Rula Sa, Guangyuan Zhao, Guangyuan Zhao, Guangyuan Zhao, Guangyuan Zhao, Hui Guo, Hui Guo, Hui Guo, Hui Guo, Gang Chen, Gang Chen, Gang Chen, Gang Chen   +21 more
doaj   +1 more source

415. Refractory ANCA vasculitis treated with Daratumumab

, 2022
Background/Objectives: ANCA-associated vasculitis (AAV) refractory to induction treatment with rituximab and cyclophosphamide is a critical clinical problem with no evidence-based options and high associated morbidity and mortality.
Lennard Ostendorf1,2,
core   +1 more source